diethyl propylphosphonite | 51825-26-4

• 分子结构分类: 有机化合物 - 有机磷化合物
• 英文名称: diethyl propylphosphonite
• 英文别名: diethyl propyl phosphite；propyl-phosphonous acid diethyl ester；Propyl-phosphonigsaeure-diaethylester；Diaethoxy-propyl-phosphin；Ethyl propylphosphonit；Diethoxy(propyl)phosphane
• CAS: 51825-26-4
• 化学式: C₇H₁₇O₂P
• 分子量: 164.185
• InChiKey: DCCVVXOAXUMESS-UHFFFAOYSA-N

物化性质

• 沸点：
  52-53 °C(Press: 12 Torr)
• 密度：
  0.9029 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  diethyl propylphosphonite 在 lithium aluminium tetrahydride 作用下， 以 甲苯 为溶剂， 反应 16.0h， 生成 n-Propylphosphin
  参考文献：
  名称：

  由有机膦酸酯制备金属三硫代膦酸酯

  摘要：

  提出了一种制备金属三卤代膦酸酯的新方法，其中首先用LiAlH 4还原有机膦酸酯，然后用有机金属试剂和元素硫或硒处理，得到所需的三卤代膦酸酯络合物。使用这种合成的协议与Ñ丁基锂作为有机金属试剂，锂trithiophosphonate配合物[李2（S 3 PCH 2 PH）（THF）（TMEDA）] 2（1）和[李4（S 3 P Ñ PR）2（ TMEDA）3 ] ∞（3），其中已经制备了THF ＝四氢呋喃且TMEDA ＝N，N，N ′，N′-四甲基乙二胺。在这两种情况下，副产物的形成也很明显，其中包括1的四硫代次二膦酸酯络合物[（PhCH 2 P（S 2））2 Li 2（THF）4 ]（2）。的更换Ñ丁基锂与Ñ卜2 Mg作为导致更清洁的产品和提高的产率，与新的和trithio- triselenoorganophosphonate配合物[Mg（上的金属化剂š 3报道了PCH 2 Ph）（TMEDA）]

  DOI：

  10.1021/ic301504p
• 作为产物：
  描述：

  乙醇 、 propylphosphorous acid tetraethyldiamide 生成 diethyl propylphosphonite
  参考文献：
  名称：

  Efimova,V.D. et al., Journal of general chemistry of the USSR, 1974, vol. 44, p. 51 - 56

  摘要：

  DOI：

文献信息

• Photoinduced Decarboxylative Radical Phosphinylation
  作者：Yulu Cheng、Jingsen Zhen、Linxiang Chai、Jian Wang、Junyue Yin、Lin Zhu、Chaozhong Li

  DOI：10.1002/anie.202316764

  日期：2024.2.19

  Reported herein is an unprecedented protocol for C(sp³)‐phosphinylation. With 1 mol % 4CzIPN (1,2,3,5‐tetrakis(carbazol‐9‐yl)‐4,6‐dicyanobenzene) as the catalyst, the visible light induced reaction of redox‐active esters of aliphatic carboxylic acids with dimethyl arylphosphonites or diethyl alkylphosphonites at room temperature provides the corresponding decarboxylative phosphinylation products in satisfactory yields. The protocol exhibits broad substrate scope and wide functional‐group compatibility, enabling the late‐stage modification of complex molecules and rapid synthesis of bioactive phosphinic acids such as glutamine synthetase phosphinothricin and a kynureninase inhibitor. A radical‐polar crossover mechanism involving the formation and subsequent oxidation of phosphoranyl radicals followed by nucleophilic demethylation (or deethylation) is proposed.

  摘要 本文报告了一种前所未有的 C(sp3)-膦酰化协议。以 1 mol % 4CzIPN （1,2,3,5-四（咔唑-9-基）-4,6-二氰基苯）为催化剂，在室温下，脂肪族羧酸的氧化还原活性酯与二甲基芳基亚膦酸盐或二乙基烷基亚膦酸盐在可见光的诱导下发生反应，以令人满意的收率得到相应的脱羧膦化产物。该方案具有广泛的底物范围和宽泛的官能团兼容性，能够对复杂分子进行后期修饰，并快速合成具有生物活性的膦酸，如谷氨酰胺合成酶phosphinothricin 和一种犬尿素酶抑制剂。提出了一种自由基-极性交叉机制，其中涉及磷酰自由基的形成和随后的氧化，然后是亲核去甲基化（或脱乙基化）。
• BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Shanghai de Novo Pharmatech Co., Ltd.

  公开号：EP3453707A1

  公开（公告）日：2019-03-13

  Disclosed are a benzazepine derivative, a preparation method, a pharmaceutical composition and the use thereof. A compound as shown in formula (I) of the present invention, and an isomer, a prodrug, a stable isotope derivative or a pharmaceutically acceptable salt thereof have the following structure. The benzazepine derivative of the present invention has a good regulation effect on the TLR family and the related signalling pathway, and in particular, has a good regulation effect on TLR8, can effectively treat, relieve and/or prevent various diseases mediated by TLR family and the TLR-related signalling pathway, and in particular, can effectively treat, relieve and/or prevent various diseases mediated by TLR8, such as cancers, autoimmune diseases, infections, inflammations, transplantation rejections, graft-versus-host diseases, etc.

  本发明公开了一种苯扎西平衍生物、一种制备方法、一种药物组合物及其用途。本发明的式(I)所示化合物及其异构体、原药、稳定同位素衍生物或药学上可接受的盐具有如下结构。本发明的苯并氮杂卓衍生物对TLR家族及相关信号通路具有良好的调节作用，特别是对TLR8具有良好的调节作用，能有效治疗、缓解和/或预防由TLR家族及TLR相关信号通路介导的各种疾病，特别是能有效治疗、缓解和/或预防由TLR8介导的各种疾病，如癌症、自身免疫性疾病、感染、炎症、移植排斥、移植物抗宿主疾病等。
• Gurevich; Akhmetova; Gubaidullin, Russian Journal of General Chemistry, 1998, vol. 68, # 9, p. 1501 - 1506
  作者：Gurevich、Akhmetova、Gubaidullin、Moskva、Litvinov

  DOI：——

  日期：——
• Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors
  作者：Gábor Németh、Zoltán Greff、Anna Sipos、Zoltán Varga、Rita Székely、Mónika Sebestyén、Zsuzsa Jászay、Szabolcs Béni、Zoltán Nemes、Jean-Luc Pirat、Jean-Noël Volle、David Virieux、Ágnes Gyuris、Katalin Kelemenics、Éva Áy、Janos Minarovits、Susan Szathmary、György Kéri、László Őrfi

  DOI：10.1021/jm401742r

  日期：2014.5.22

  Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.
• Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency
  作者：Stephen R. Bertenshaw、Roland S. Rogers、Michael K. Stern、Bryan H. Norman、William M. Moore、Gina M. Jerome、Linda M. Branson、John F. McDonald、Ellen G. McMahon、Maria A. Palomo

  DOI：10.1021/jm00053a023

  日期：1993.1